Aragen to Manufacture Renaissance Pharma’s Fast-Track mAb Kumar Jeetendra | June 3, 2026 Aragen, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has successfully tech-transferred and manufactured the first commercial-scale GMP batches of Renaissance Pharma’s lead candidate, Daretabart – a humanized monoclonal antibody targeting GD2 for high-risk neuroblastoma – in just 9 months. The anti-GD2 monoclonal antibody received Fast Track Designation from the FDA in April 2026 for …
Cipla, SBP Group Sign Exclusive License for HER2 Bispecific ADC Kumar Jeetendra | September 7, 2026 Cipla Limited (BSE: 500087; NSE: CIPLA) (“Cipla”) and Sino Biopharmaceutical Limited (HKEX: 1177) (“SBP Group”) today announced that SBP Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“CTTQ”), has entered into an exclusive license and supply agreement with Cipla for Rolditamig Deuderuxtecan, also known as TQB2102, a potential best-in-class HER2 bispecific antibody-drug conjugate (“ADC”). …
